to see how well the therapy of AK117/placebo combined with Azacitidine fights Higher-risk Myelodysplastic Syndrome and how safe it is.
If you decide to take part, you will receive medication given by blood via a vein every two weeks. Azacitidine will be given under the skin/subcutaneously. At each visit you will be asked questions about your health and medications you are taking. You will also answer questionnaires. Blood draws for routine tests should be expected at every visit on site. You will also have to give samples of salvia, or bone marrow, physical exam, chest
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Joshua Zeidner
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Leukemia)
24-0365